The global nutrigenomics (nutritional genomics) market was valued at USD 521.4 million in 2025. The market is estimated at USD 584.3 million in 2026 and is projected to reach USD 1.73 billion by 2036, at a CAGR of 11.5% during the forecast period 2026-2036. This report assesses the science of gene-nutrient interactions, testing technologies, business models, claim regulation, the value chain, pricing, the competitive landscape, and future growth opportunities.
The market covers offerings that use genetic and related molecular data to shape dietary advice, nutrition products, and nutrient-genome research, including tests sold directly or via practitioners, reagents and panels for nutritional genomics research, recommendation algorithms and practitioner platforms, and supplements, foods, and meal services chosen from test results. Nutrigenetics looks at how genetic variation changes a person's response to nutrients, while nutrigenomics looks at how nutrients affect gene expression, and most commercial offerings combine both. General supplements not linked to individual testing, clinical diagnostic genetic testing, standalone microbiome tests, and dietetic consultations without molecular testing are excluded.
Specific gene-nutrient links, such as variants affecting caffeine and folate metabolism, lactose digestion, and sodium sensitivity, are well supported, but most dietary outcomes depend on many genes, behavior, and environment. According to a U.K. Food Standards Agency review, the science holds up well in clinical use but falls short for consumer applications, about 50 genomics-based personalized nutrition providers operate worldwide, around 15 of them in the U.K., and most customers buy once out of curiosity or subscribe for only a few months. Investor interest in multi-omic approaches remains strong, with Viome Life Sciences raising USD 175 million for its at-home testing, which uses Los Alamos National Laboratory technology to read microbial and human gene expression from one sample.
The evidence base is stronger in research than in consumer use, and professional bodies in dietetics and clinical nutrition remain cautious about genotype-based advice, holding back clinical uptake and reimbursement. Weak retention is a second restraint, since a fixed genetic report gives customers little reason to return. Claim regulation is a further challenge: the U.S. Federal Trade Commission settled with a seller of genetically customized supplements over unsupported claims, confirming that genetic personalization does not exempt a product from substantiation rules. With no shared standards for validating algorithms, two providers can give different advice from the same genotype, while phenotype-based personalization using glucose, microbiome, and blood data competes without any genetic test.
Personalized supplement and functional food subscriptions are a major opportunity, as a test that leads to a recurring product addresses the retention problem and raises customer lifetime value. Multi-omic monitoring, expansion through dietitians and physicians who treat obesity, diabetes, and cardiovascular risk, and research work for food and supplement companies also offer openings. Key trends include the move from genotype-only reports to multi-omic services, a shift from direct consumer sales toward practitioner, employer, and enterprise channels, and the convergence of testing with personalized product formulation and fulfillment.
By offering, the nutrigenomics market is segmented into nutrigenomic testing services (genotype-only testing and multi-omic testing), research products & reagents, interpretation software & platforms, and personalized nutrition & supplement products (personalized supplements and personalized food & meal services). Nutrigenomic testing services are expected to hold the largest share in 2026, since the test is the starting point for every nutrigenomic offering, panels are sold through both consumer and practitioner channels, and established providers supply tests through registered dietitians and nutritionists. Personalized nutrition & supplement products are projected to record the highest CAGR, as providers move from a one-off test to a repeat product based on it, personalization supports premium pricing, and supplement and nutrition companies are investing in subscription models. Multi-omic testing is gaining ground on genotype-only testing.
By technology, the nutrigenomics market is segmented into genotyping arrays & targeted panels, sequencing-based approaches, gene expression & transcriptomic analysis, and integrated multi-omic platforms. Genotyping arrays & targeted panels are expected to account for the largest share in 2026, as genotyping a defined set of known variants is inexpensive, fits consumer price points, and matches how most commercial panels are built. Integrated multi-omic platforms are projected to grow at the highest CAGR, because fixed genotype data cannot show a response to diet, investment is flowing to multi-omic approaches, and platforms that combine genetic, microbiome, and metabolic data support monitoring and subscriptions.
By application, the nutrigenomics market is segmented into weight management & obesity, metabolic & cardiovascular health, sports & performance nutrition, food intolerance & sensitivity, micronutrient status & supplementation, and other applications such as healthy aging and gut health. Weight management & obesity is expected to hold the largest share in 2026, reflecting huge consumer demand for weight solutions, the appeal of explaining why standard diets have failed, and strong willingness to pay. Metabolic & cardiovascular health is projected to register the highest CAGR, driven by the clinical relevance of gene-diet links in lipid metabolism, sodium sensitivity, and glucose control, the use of glucose monitors alongside genetic and microbiome results, and better prospects for clinical and employer funding where risk factors can be shown to improve. Sports nutrition is a high-value application focused on caffeine timing, recovery, and micronutrient needs.
By distribution channel, the nutrigenomics market is segmented into direct-to-consumer online, practitioner & clinical channels, employer, insurer & wellness programs, and retail & other channels. Direct-to-consumer online is expected to account for the largest share in 2026, since the category grew out of wellness tests sold online, often alongside consumer genetic testing, and still relies on digital marketing. Practitioner & clinical channels are projected to grow at the highest CAGR, as professional involvement improves interpretation and retention, lowers regulatory risk on claims, and gives access to clinical patients who are more engaged than general wellness buyers. Employer, insurer, and wellness programs add volume at low acquisition cost.
By end user, the nutrigenomics market is segmented into individual consumers, dietitians, nutritionists & clinical practitioners, food, beverage & supplement companies, sports organizations & fitness providers, and academic & research institutes. Individual consumers are expected to account for the largest share in 2026, as the category is funded mostly by personal wellness spending on tests, reports, and personalized supplement subscriptions. Food, beverage & supplement companies are projected to record the highest CAGR, as they use personalization to differentiate products and drive subscriptions, apply nutrigenomic research to support claims, and offer personalization platforms to brands. Research institutes add steady demand from precision nutrition studies.
North America is expected to lead the global nutrigenomics market in 2026, owing to high consumer spending on wellness services, a large supplement industry used to direct subscription models, the concentration of nutrigenomic testing and multi-omic companies, and many functional and integrative medicine practitioners who use genetic panels. Europe holds a significant position, backed by health-aware consumers and strong nutrition research, with the U.K. and Nordic markets among the most active, although stricter claim rules, the GDPR, and limits on non-medical genetic testing slow growth.
Asia-Pacific is expected to be the fastest-growing region through 2036, supported by rising incomes and health awareness across China, Japan, South Korea, and India, a strong cultural view of diet as the basis of good health, a large and expanding functional food and supplement industry, and consumer genetic testing demand that leans toward wellness and nutrition rather than genealogy. Latin America and the Middle East & Africa account for smaller shares; growing wellness and supplement markets support demand in Brazil and Mexico, while high rates of diabetes and obesity, disposable income, and interest in preventive health support growth in Saudi Arabia and the UAE.
The nutrigenomics market is fragmented and at an early stage, with no provider holding a dominant position and wide differences in scientific rigor. Participants include practitioner-channel providers such as Nutrigenomix and GX Sciences, multi-omic companies such as Viome and Zoe, wellness brands such as DNAfit and GenoPalate, ingredient companies such as dsm-firmenich, and tool suppliers such as Thermo Fisher Scientific and Illumina. Companies compete on the scientific strength of their panels and algorithms, claim credibility, practitioner relationships, multi-omic integration, and subscription retention. Main strategies include adding dynamic measurement to genetic tests, shifting from reports to personalized products, growing practitioner and enterprise sales, and building evidence to support claims, while recent developments include Viome's funding round for multi-omic at-home testing.
Key companies profiled in the report include Viome Life Sciences, Inc. (U.S.), Zoe Limited (U.K.), Nutrigenomix Inc. (Canada), GX Sciences, LLC (U.S.), GenoPalate Inc. (U.S.), Prenetics Global Limited (DNAfit) (Hong Kong), dsm-firmenich AG (Switzerland), Metagenics, LLC (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Illumina, Inc. (U.S.).
The market covers offerings that use genetic and related molecular data to shape dietary advice, nutrition products, and nutrient-genome research, including tests sold directly or via practitioners, reagents and panels for nutritional genomics research, recommendation algorithms and practitioner platforms, and supplements, foods, and meal services chosen from test results. Nutrigenetics looks at how genetic variation changes a person's response to nutrients, while nutrigenomics looks at how nutrients affect gene expression, and most commercial offerings combine both. General supplements not linked to individual testing, clinical diagnostic genetic testing, standalone microbiome tests, and dietetic consultations without molecular testing are excluded.
Specific gene-nutrient links, such as variants affecting caffeine and folate metabolism, lactose digestion, and sodium sensitivity, are well supported, but most dietary outcomes depend on many genes, behavior, and environment. According to a U.K. Food Standards Agency review, the science holds up well in clinical use but falls short for consumer applications, about 50 genomics-based personalized nutrition providers operate worldwide, around 15 of them in the U.K., and most customers buy once out of curiosity or subscribe for only a few months. Investor interest in multi-omic approaches remains strong, with Viome Life Sciences raising USD 175 million for its at-home testing, which uses Los Alamos National Laboratory technology to read microbial and human gene expression from one sample.
Market Dynamics
Rising consumer and clinical interest in diet plans tailored to the individual is a major driver of the nutrigenomics market, as people question one-size-fits-all dietary guidance and practitioners treating obesity, metabolic syndrome, and cardiovascular risk look for tools that improve adherence. Providers are also combining genetic data with microbiome, metabolomic, blood biomarker, and continuous glucose data; because a genotype never changes, these dynamic measures let a service show whether an intervention is working and support ongoing monitoring. Dietitians, functional medicine practitioners, and sports organizations are adopting nutrigenomic panels as an assessment tool, and ingredient and supplement companies such as dsm-firmenich are investing in personalization to differentiate products and sell them on subscription.The evidence base is stronger in research than in consumer use, and professional bodies in dietetics and clinical nutrition remain cautious about genotype-based advice, holding back clinical uptake and reimbursement. Weak retention is a second restraint, since a fixed genetic report gives customers little reason to return. Claim regulation is a further challenge: the U.S. Federal Trade Commission settled with a seller of genetically customized supplements over unsupported claims, confirming that genetic personalization does not exempt a product from substantiation rules. With no shared standards for validating algorithms, two providers can give different advice from the same genotype, while phenotype-based personalization using glucose, microbiome, and blood data competes without any genetic test.
Personalized supplement and functional food subscriptions are a major opportunity, as a test that leads to a recurring product addresses the retention problem and raises customer lifetime value. Multi-omic monitoring, expansion through dietitians and physicians who treat obesity, diabetes, and cardiovascular risk, and research work for food and supplement companies also offer openings. Key trends include the move from genotype-only reports to multi-omic services, a shift from direct consumer sales toward practitioner, employer, and enterprise channels, and the convergence of testing with personalized product formulation and fulfillment.
Segment Analysis
The report analyzes the market by offering, technology, application, distribution channel, end user, and geography, helping stakeholders identify the most attractive areas for product development, partnerships, and investment.By offering, the nutrigenomics market is segmented into nutrigenomic testing services (genotype-only testing and multi-omic testing), research products & reagents, interpretation software & platforms, and personalized nutrition & supplement products (personalized supplements and personalized food & meal services). Nutrigenomic testing services are expected to hold the largest share in 2026, since the test is the starting point for every nutrigenomic offering, panels are sold through both consumer and practitioner channels, and established providers supply tests through registered dietitians and nutritionists. Personalized nutrition & supplement products are projected to record the highest CAGR, as providers move from a one-off test to a repeat product based on it, personalization supports premium pricing, and supplement and nutrition companies are investing in subscription models. Multi-omic testing is gaining ground on genotype-only testing.
By technology, the nutrigenomics market is segmented into genotyping arrays & targeted panels, sequencing-based approaches, gene expression & transcriptomic analysis, and integrated multi-omic platforms. Genotyping arrays & targeted panels are expected to account for the largest share in 2026, as genotyping a defined set of known variants is inexpensive, fits consumer price points, and matches how most commercial panels are built. Integrated multi-omic platforms are projected to grow at the highest CAGR, because fixed genotype data cannot show a response to diet, investment is flowing to multi-omic approaches, and platforms that combine genetic, microbiome, and metabolic data support monitoring and subscriptions.
By application, the nutrigenomics market is segmented into weight management & obesity, metabolic & cardiovascular health, sports & performance nutrition, food intolerance & sensitivity, micronutrient status & supplementation, and other applications such as healthy aging and gut health. Weight management & obesity is expected to hold the largest share in 2026, reflecting huge consumer demand for weight solutions, the appeal of explaining why standard diets have failed, and strong willingness to pay. Metabolic & cardiovascular health is projected to register the highest CAGR, driven by the clinical relevance of gene-diet links in lipid metabolism, sodium sensitivity, and glucose control, the use of glucose monitors alongside genetic and microbiome results, and better prospects for clinical and employer funding where risk factors can be shown to improve. Sports nutrition is a high-value application focused on caffeine timing, recovery, and micronutrient needs.
By distribution channel, the nutrigenomics market is segmented into direct-to-consumer online, practitioner & clinical channels, employer, insurer & wellness programs, and retail & other channels. Direct-to-consumer online is expected to account for the largest share in 2026, since the category grew out of wellness tests sold online, often alongside consumer genetic testing, and still relies on digital marketing. Practitioner & clinical channels are projected to grow at the highest CAGR, as professional involvement improves interpretation and retention, lowers regulatory risk on claims, and gives access to clinical patients who are more engaged than general wellness buyers. Employer, insurer, and wellness programs add volume at low acquisition cost.
By end user, the nutrigenomics market is segmented into individual consumers, dietitians, nutritionists & clinical practitioners, food, beverage & supplement companies, sports organizations & fitness providers, and academic & research institutes. Individual consumers are expected to account for the largest share in 2026, as the category is funded mostly by personal wellness spending on tests, reports, and personalized supplement subscriptions. Food, beverage & supplement companies are projected to record the highest CAGR, as they use personalization to differentiate products and drive subscriptions, apply nutrigenomic research to support claims, and offer personalization platforms to brands. Research institutes add steady demand from precision nutrition studies.
Regional Analysis
The report covers North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa, spanning 15 countries, the Nordic countries, and four rest-of-region groups. The regional analysis of the nutrigenomics market considers wellness spending, practitioner adoption, provider presence, and national rules on health claims and genetic testing.North America is expected to lead the global nutrigenomics market in 2026, owing to high consumer spending on wellness services, a large supplement industry used to direct subscription models, the concentration of nutrigenomic testing and multi-omic companies, and many functional and integrative medicine practitioners who use genetic panels. Europe holds a significant position, backed by health-aware consumers and strong nutrition research, with the U.K. and Nordic markets among the most active, although stricter claim rules, the GDPR, and limits on non-medical genetic testing slow growth.
Asia-Pacific is expected to be the fastest-growing region through 2036, supported by rising incomes and health awareness across China, Japan, South Korea, and India, a strong cultural view of diet as the basis of good health, a large and expanding functional food and supplement industry, and consumer genetic testing demand that leans toward wellness and nutrition rather than genealogy. Latin America and the Middle East & Africa account for smaller shares; growing wellness and supplement markets support demand in Brazil and Mexico, while high rates of diabetes and obesity, disposable income, and interest in preventive health support growth in Saudi Arabia and the UAE.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, the competitive dashboard with market leaders, market differentiators, vanguards, and emerging players, and funding and investment analysis. Company profiles include business overviews, financial overviews, test and product portfolios, scientific basis and claims position, channel strategy, strategic developments, and SWOT analyses.The nutrigenomics market is fragmented and at an early stage, with no provider holding a dominant position and wide differences in scientific rigor. Participants include practitioner-channel providers such as Nutrigenomix and GX Sciences, multi-omic companies such as Viome and Zoe, wellness brands such as DNAfit and GenoPalate, ingredient companies such as dsm-firmenich, and tool suppliers such as Thermo Fisher Scientific and Illumina. Companies compete on the scientific strength of their panels and algorithms, claim credibility, practitioner relationships, multi-omic integration, and subscription retention. Main strategies include adding dynamic measurement to genetic tests, shifting from reports to personalized products, growing practitioner and enterprise sales, and building evidence to support claims, while recent developments include Viome's funding round for multi-omic at-home testing.
Key companies profiled in the report include Viome Life Sciences, Inc. (U.S.), Zoe Limited (U.K.), Nutrigenomix Inc. (Canada), GX Sciences, LLC (U.S.), GenoPalate Inc. (U.S.), Prenetics Global Limited (DNAfit) (Hong Kong), dsm-firmenich AG (Switzerland), Metagenics, LLC (U.S.), Thermo Fisher Scientific Inc. (U.S.), and Illumina, Inc. (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global nutrigenomics market.
- Explains how personalized nutrition demand, multi-omic integration, practitioner adoption, and industry investment are shaping growth.
- Assesses the impact of evidence gaps, weak retention, claim regulation, and phenotype-based competition on providers.
- Identifies high-growth opportunities across offering, technology, application, distribution channel, end user, and region.
- Tracks the shift from genotype-only reports to multi-omic services and test-informed product subscriptions.
- Benchmarks leading companies on scientific basis, claims position, channel strategy, and funding.
- Supports product, channel, partnership, and market entry decisions for testing providers, supplement companies, and investors.
Key Questions Answered
- How big is the global nutrigenomics market today, and how will it grow through 2036?
- How strong is the scientific evidence behind nutrigenomic advice, and how does it affect commercial adoption?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How are multi-omic testing and continuous monitoring changing nutrigenomic services?
- How do FTC enforcement, health claim rules, and the U.K. Food Standards Agency review affect providers?
- Which offerings, technologies, applications, distribution channels, and end users will grow the fastest?
- How are providers addressing poor customer retention through subscriptions and personalized products?
- Which regions and countries offer the most attractive business opportunities?
- Who are the leading companies, and what strategies are they using to strengthen their position?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Insights
5. Nutrigenomics Market Assessment, by Offering
6. Nutrigenomics Market Assessment, by Technology
7. Nutrigenomics Market Assessment, by Application
8. Nutrigenomics Market Assessment, by Distribution Channel
9. Nutrigenomics Market Assessment, by End User
10. Nutrigenomics Market Assessment, by Geography
11. Competition Analysis
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Viome Life Sciences, Inc.
- Zoe Limited
- Nutrigenomix Inc.
- GX Sciences, LLC
- GenoPalate Inc.
- Prenetics Global Limited
- dsm-firmenich AG
- Metagenics, LLC
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
